Literature DB >> 7544984

Controlled, targeted, intracellular expression of ribozymes: progress and problems.

J J Rossi1.   

Abstract

Significant progress has been made in the development of ribozymes for a wide variety of intracellular applications, including human gene therapy. Further advances are likely to come from innovative strategies to improve the delivery, expression, co-localization, targeting specificity and substrate turnover of ribozymes. In order to stimulate problem solving in these areas, this article discusses examples of recent successes in intracellular ribozyme applications, and identifies some of the obstacles that remain. In addition, some testable, but as yet untried, ideas for overcoming several of these obstacles are presented.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544984     DOI: 10.1016/S0167-7799(00)88969-6

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  23 in total

Review 1.  Engineering the plant cell factory for secondary metabolite production.

Authors:  R Verpoorte; R van der Heijden; J Memelink
Journal:  Transgenic Res       Date:  2000       Impact factor: 2.788

2.  Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.

Authors:  R Goila; A C Banerjea
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

3.  Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors:  T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

4.  Measurements of weak interactions between truncated substrates and a hammerhead ribozyme by competitive kinetic analyses: implications for the design of new and efficient ribozymes with high sequence specificity.

Authors:  Yasuhiro Kasai; Hideki Shizuku; Yasuomi Takagi; Masaki Warashina; Kazunari Taira
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

5.  A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency.

Authors:  D A Samarsky; G Ferbeyre; E Bertrand; R H Singer; R Cedergren; M J Fournier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  Functional repair of a mutant chloride channel using a trans-splicing ribozyme.

Authors:  Christopher S Rogers; Carlos G Vanoye; Bruce A Sullenger; Alfred L George
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

7.  Ribozymes that cleave reovirus genome segment S1 also protect cells from pathogenesis caused by reovirus infection.

Authors:  S Shahi; G K Shanmugasundaram; A C Banerjea
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

8.  Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.

Authors:  G Grassi; A Forlino; J C Marini
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

Review 9.  Hammerhead ribozyme kinetics.

Authors:  T K Stage-Zimmermann; O C Uhlenbeck
Journal:  RNA       Date:  1998-08       Impact factor: 4.942

10.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.